Mannose-binding lectin (MBL) is synthesized by the liver and binds to microbes. MBL2 gene polymorphisms produce intermediate/low/null or normal MBL serum levels (MBL-deficient or MBL-sufficient phenotypes, respectively). We aimed to evaluate the incidence and severity of infection, rejection, and survival within 1 year after liver transplantation (LT) according to donor and recipient MBL2 gene polymorphisms. A repeated-event analysis for infection episodes (negative binomial regression, AndersenGill model) was performed in 240 LTs. Four hundred twenty-eight infectious episodes (310 bacterial, 15 fungal, 65 cytomegalovirus [CMV]-related, and 38 viral non-CMV-related episodes) and 48 rejection episodes were recorded. The main bacterial infections were urinary (n = 82, 26%) and pneumonia (n = 69, 22%). LT recipients of MBL-deficient livers had a higher risk of bacterial infection (incidence rate ratio The 1-year bacterial infection-related mortality was higher in recipients of MBL-deficient versus MBL-sufficient livers (65.8% vs. 56.1%, respectively; p = 0.0097). The incidence of rejection, viral, or fungal infection was similar in both groups. Recipient MBL2 genotype did not significantly increase the risk of bacterial infection. LT recipients of MBL-deficient livers have a higher risk of bacterial infection, pneumonia, septic shock, and 1-year bacterial infection-related mortality after LT.
Mannose-binding lectin (MBL) is synthesized by the liver and binds to microbes. MBL2 gene polymorphisms produce intermediate/low/null or normal MBL serum levels (MBL-deficient or MBL-sufficient phenotypes, respectively). We aimed to evaluate the incidence and severity of infection, rejection, and survival within 1 year after liver transplantation (LT) according to donor and recipient MBL2 gene polymorphisms. A repeated-event analysis for infection episodes (negative binomial regression, AndersenGill model) was performed in 240 LTs. Four hundred twenty-eight infectious episodes (310 bacterial, 15 fungal, 65 cytomegalovirus [CMV]-related, and 38 viral non-CMV-related episodes) and 48 rejection episodes were recorded. The main bacterial infections were urinary (n = 82, 26%) and pneumonia (n = 69, 22%). LT recipients of MBL-deficient livers had a higher risk of bacterial infection (incidence rate ratio The 1-year bacterial infection-related mortality was higher in recipients of MBL-deficient versus MBL-sufficient livers (65.8% vs. 56.1%, respectively; p = 0.0097). The incidence of rejection, viral, or fungal infection was similar in both groups. Recipient MBL2 genotype did not significantly increase the risk of bacterial infection. LT recipients of MBL-deficient livers have a higher risk of bacterial infection, pneumonia, septic shock, and 1-year bacterial infection-related mortality after LT.
Introduction
Mannose-binding lectin (MBL) is a serum protein synthesized by the liver that plays a pivotal role in innate immunity by aiding in the clearance of microbes and endogenous waste material. MBL recognizes microbial agents and "altered-self" cells through pathogen-associated molecular patterns and damage-associated molecular patterns, respectively (1) . MBL attaches to mannose and Nacetyl-glucosamine residues on the surface of microorganisms to initiate the activation of complement, phagocytosis, and modulation of inflammatory responses (2) .
MBL is encoded by the MBL2 gene on chromosome 10. Three common polymorphisms in exon 1 of the MBL2 gene induce the replacement of amino acids in the collagen domain, altering their ability to oligomerize in serum and leading to the development of a variant form with reduced biological activity and low serum levels (haplotype O) compared with wild-type forms (haplotype A). Three additional polymorphisms in the proximal promoter region (H/L, P/Q, and Y/X) also regulate protein expression and serum levels. The biological activity and serum levels of MBL differ according to the presence of different combinations of these polymorphisms. Homozygous carriers for wild-type MBL2 haplotypes present high serum MBL levels (>1000 ng/mL), whereas patients with exon 1 and promoter variants have intermediate (200-1000 ng/mL) and low/null (<200 ng/mL) serum MBL levels (3) . MBL2 haplotypes associated with intermediate and low/null MBL serum levels (MBL-deficient haplotypes) confer a higher risk of severe infections, particularly in newborns and children, in whom adaptive immunity is not yet fully functional. However, these defective haplotypes also increase the risk of recurrent infection in adults (4), suggesting the presence of an association between MBL2 haplotypes, MBL serum levels and activity, and the risk of infection.
After liver transplantation (LT), serum MBL levels depend on the MBL2 haplotype of the liver graft. Several reports have suggested that livers from donors with MBLdeficient haplotypes may confer a higher risk of bacterial infection, cytomegalovirus (CMV) disease, and infectionrelated mortality after LT (5) (6) (7) (8) (9) . In a recent study, deceased donor kidney transplant recipients with MBLdeficient haplotypes also showed a higher 1-year incidence of acute cellular rejection (3). Nonetheless, there are inconclusive data regarding the role of MBL2 gene polymorphisms after LT due to contradictory results from previous studies (10) , the lack of analysis per infectious episodes as repetitive events, and the lack of studies specifically assessing graft rejection and patient survival.
The aim of the present study was to assess the role of donor and recipient MBL2 haplotypes in the incidence, severity, and outcomes of bacterial infection episodes, CMV infection/disease, cellular rejection, and patient survival within 1 year after LT by performing a repeatedevent analysis in a large cohort of patients.
Patients and Methods
All the patients undergoing LT at the Hospital Cl ınic of Barcelona (Spain) between January 2007 and January 2014 were considered eligible for the study. All patients gave informed consent to participate in the study, and donor data and samples were obtained according to Spanish regulations. Clinical data were obtained from our prospective LT database and were cross-checked with patient clinical charts and the microbiology database, if necessary. The following patient data were collected before LT: demographics, cause of liver disease, severity of liver disease, presence of hepatocellular carcinoma (HCC), serologic status of HIV infection, diabetes mellitus, kidney function, CMV status, surgical data (blood and plasma transfusion, cold ischemia time), and post-LT variables within 1 year after LT (immunosuppressive regimen, early allograft dysfunction, repeat intervention, biopsy-proved acute cellular rejection [BPAR] episodes, biliary complications, infections [number, date, site, severity], and patient and graft survival). The donor variables collected included age, gender, cause of death, and CMV serology. All the recipients were followed until 1 year after LT, repeat transplantation, or death with no missing data. Whole blood samples from the donor and recipient were stored at À80°C until final analysis.
Management of study patients
All LT recipients were managed by LT hepatologists and transplant surgeons according to standardized protocols throughout the follow-up period. Before 2010, the initial immunosuppression regimen consisted of steroids plus calcineurin inhibitors from day 0 (tacrolimus trough levels 10-12 ng/mL). In recipients with refractory ascites or creatinine >1.5 mg/dL before LT, mycophenolate mofetil was started at day 0 and calcineurin inhibitor administration was delayed until day 3 after LT (tacrolimus trough levels 8-10 ng/mL). Since 2010, the initial immunosuppression regimen in patients with Child-Pugh B-C or creatinine values >1.5 mg/dL consists of a single dose of basiliximab 20 mg intravenously, steroids, mycophenolate mofetil, and delayed initiation of calcineurin inhibitors (day 5, tacrolimus trough levels 6-8 ng/mL). Child-Pugh A patients or those with noncirrhotic liver disease and preserved kidney function received steroids plus calcineurin inhibitors from day 0 (tacrolimus trough levels 8-10 ng/mL). Cyclosporine administration was restricted to recipients with pretransplantation diabetes mellitus.
All patients received surgical prophylaxis with ceftazidim plus teicoplanin for 2 days. Fungal prophylaxis with nystatin was prescribed for 1 month. Prophylactic fluconazole was used concomitantly with wide-spectrum antibiotics for >3 days. Recipients with sustained acute kidney injury (creatinine values >2.5 mg/dl) or renal replacement therapy after LT, repeat intervention in the early posttransplantation period (<3 days), or a positive galactomannan antigen test received intravenous liposomal amphotericin B (3 mg/kg/day) for at least 1 week. Trimethoprim-sulfamethoxazole (160 mg/800 mg) was prescribed every other day for 1 year as prophylaxis against Pneumocystis jiroveci. Prophylactic oral valganciclovir (450 mg twice a day for 100 days) was given to high-risk patients (IgG anti-CMV donor-positive recipient-negative). All patients were monitored for CMV viral load weekly for the first 2 months and at least monthly during the following 6 months after LT. CMV infection was treated with 900 mg twice daily of oral valganciclovir for 14 days or until levels were undetectable. CMV disease was treated with intravenous ganciclovir until quantitative nucleic acid amplification tests were negative. All patients were regularly followed in the transplant clinic of the Liver Unit of our hospital.
Definition of infection and septic shock
Bacterial infections were defined according to the Centers for Disease Control and Prevention (CDC) guidelines (11) as (a) a positive culture of a pathogenic microorganism in any sample; (b) isolation of a potentially pathogenic microorganism in a sample from any location accompanied by symptoms compatible with infection; (c) an infection suggested by clinical data without microbiological isolation that was resolved completely with antimicrobial treatment. Fungal infections were defined according to the criteria proposed by the European Organization on Research and Treatment in Cancer and the Mycoses Study Group (12) . CMV infection was defined as asymptomatic CMV DNA >1000 copies/mL. CMV disease was defined as positive CMV-DNA plus viral syndrome or end-organ disease confirmed by immuno/histological findings (13) . Febrile episodes were excluded from the analysis if no microorganism was isolated and no antimicrobial treatment was given with clinical resolution of the episode or if a definitive diagnosis was provided that precluded an infectious agent. Septic shock was defined as persisting hypotension requiring vasopressors to maintain mean arterial pressure at 65 mmHg and having a serum lactate level >2 mmol/L (18 mg/dL) despite adequate volume resuscitation (14) .
MBL2 genotyping and definition of the MBL groups
Genotyping of MBL2 was done by polymerase chain reaction and sequence-based typing technique including the region from the promoter to the end of exon 1 as reported previously (8) . Genetic groups were defined according to the phenotypic correlates with MBL serum values: "A" designates the wild-type allele (normal serum levels) and "O" designates the variant-type allele, with any of the three structural mutations (B, C, and D) reported at exon 1 (decreased serum levels). The following groups were defined for promoter and untranslated region polymorphisms: (1) allele H/L promoter-550: high producers (HH) and low producers (HL or LL); (2) allele P/Q: high producers (QQ) and low producers (PP and PQ); (3) allele Y/X promoter-221: high producers (YY and YX) and low producers (XX). As published elsewhere, the combinations of the promoter-221 and exon 1 polymorphisms were used as the working haplotype: MBL-sufficient livers (YA/YA and YA/XA, normal serum MBL levels), and the remaining combinations as MBL-deficient livers (intermediate/low serum MBL levels: XA/XA and YA/YO; low/null serum MBL levels producers: YO/YO, XA/YO). Donor MBL2-genotyping was performed in 240 donors and 235 recipients (genotyping could not be performed in five).
Sample size and statistical analysis
Two hundred thirty-six LT recipients were needed to detect different patient survival (expected 1-year survival 91% vs. 78% according to previous results), and 234 LT recipients were needed to detect a different risk of infection (expected 1-year incidence of infection in LT recipients of MBL-sufficient vs. MBL-deficient livers: 50% vs. 66%, respectively). The sample size was calculated for a power of 80% and a level of significance of 95%.
Repeated-events analysis was performed for bacterial infection episodes, site of infection, bacteria isolated, and septic shock. The incidence rate ratio (IRR), which expresses the ratio between the incidences of events between MBL-deficient and MBL-sufficient liver grafts with a confidence interval (95% CI), was calculated. To assess the risk of repeated events (infection, pneumonia, among others), we performed negative binomial regression or Poisson regression (as appropriate according to the variance and dispersion of variables) adjusted for clinically significant variables. We performed a time-dependent analysis using an extension of the Cox model (Andersen-Gill model) to assess the risk of multiple infection episodes and to obtain the cumulative incidence function (15) . Statistical analysis was performed by using the SPSS v23.0 (SPSS, Inc., Chicago, IL) statistical package and SAS/STAT software v9.4 (SAS Institute Inc., Cary, NC). A per-patient analysis was also performed by using KaplanMeier survival curves and a Cox proportional-hazard model for analysis of the first episode of infection.
Results
The study included 240 of the 562 LT procedures performed at our institution from January 1, 2007, to January 30th, 2014. The mean (standard deviation) follow-up was 339 (79) days. Patients not providing informed consent or lacking donor blood to carry out MBL2 genotyping (n = 322) were excluded from the study. Table 1 shows the baseline characteristics, donor variables, surgical data, and graft outcomes. Chronic endstage liver disease (ESLD), with or without HCC, was the main indication for LT, and the median MELD at transplantation was 20 (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . The causes of ESLD before LT were hepatitis C virus (HCV) infection (n = 114, 47%), alcohol (n = 67, 28%), hepatitis B virus (HBV) infection (n = 12, 5%), cholestatic diseases (n = 10, 4%), nonalcoholic steatohepatitis (n = 9, 4%) and other causes (n = 28, 12%). The most common causes of acute liver failure were idiopathic (n = 6, 40%) and drug induced or toxic (n = 4, 26%). No patient had active infection immediately before LT, and there were no living donors in our study cohort. The overall incidence of BPAR, biliary complications, and patient survival at 1 year in the study cohort (n = 240) was not different from that of the 322 LT recipients during the same time period without informed consent or donor blood available to perform MBL2 genotyping (20% vs. 13.7%, p = 0.40; 16.2% vs. 14.1%, p = 0.73; and 87.4 vs. 93.7%, log rank = 0.07; respectively). The baseline characteristics (Table 1) of the LT recipients of MBL-deficient livers (n = 113, 47.9%) versus MBL-sufficient livers (n = 127, 52.1%) were comparable. We observed no HCC recurrence within 1 year after LT.
A total of 428 infectious episodes were recorded within 1 year after LT: 310 bacterial, 15 fungal, 65 CMV-related, and 38 viral non-CMV-related episodes. Table 2 shows the percentage of LT recipients who developed at least one bacterial, fungal, or viral infection within 1 year after LT. One-third of LT recipients (n = 80) had no infection, 38% (n = 91) had one type of microbial infection (bacterial, fungal, or viral), 22% (n = 54) had two types of microbial infection, and 6% (n = 15) had bacterial, fungal, and viral infections during follow-up.
Bacterial infections
The per-patient analysis showed the percentage of LT recipients who developed at least one bacterial, fungal, or viral infection within 1 year after LT ( Table 2 and Supplementary Information).
A repeated-events analysis of the 310 bacterial infection episodes was used to assess the risk of infection (Table 3 ). The incidence of bacterial infection was higher in LT recipients of MBL-deficient versus MBL-sufficient livers (IRR [CI] 1.48 [1.044-2.088], p = 0.028), with an increased cumulative incidence of bacterial infection episodes ( Figure 1A ; log rank = 0.0035).
Results of the analysis of the site of infection and microbial isolations of the 310 bacterial infection episodes are shown in Table 3 Table 3 ). The cumulative incidence of pneumonia was also higher in LT recipients of MBL-sufficient versus MBL-deficient livers ( Figure 1A ; p = 0.0048). This increased number of bacterial pneumonia episodes was observed within the first 7 days and between days 7 and 365 after LT (24.7% vs. 12.6% and 15.9% vs. 3.9%; p = 0.008 and p = 0.007, respectively). The detection of P. aeruginosa was mainly related to the presence of pneumonia and urinary tract infections (13 vs. 3 isolates and 4 vs. 0 isolates in LT recipients of MBL-sufficient vs. MBL-deficient livers; p = 0.008 and p = 0.035, respectively) and catheter-related infection (seven vs. five isolates, p = 0.44).
Septic shock and survival A total of 18 LT recipients had 24 episodes of bacterial septic shock within 1 year after LT. The infection sites for septic shock episodes were pulmonary (n = 8), intraabdominal (n = 9), urinary tract (n = 2), and others (n = 5). Recipients of an MBL-deficient versus an MBLsufficient liver had a higher incidence of bacterial septic shock (IRR [CI] 5.62 [1.92-16.4 ], p = 0.002). In the negative binomial regression multivariate analysis, LT recipients of MBL-sufficient versus MBL-deficient livers had an increased risk of developing bacterial infection, bacterial pneumonia, septic shock, and P. aeruginosa infection after LT (Table 4) . A higher MELD score, fulminant hepatic failure, and HCV infection also increased the risk of bacterial infection after LT. However, when excluding infectious episodes occurring between 3 and 12 months after LT, HCV infection was no longer a predictive factor for bacterial infection. MBL-deficient recipients with a MELD score ≥22 at transplantation with an MBLdeficient donor were those at highest risk of bacterial infection (IRR 7.263 [3.102-17 .006], p = 0.000, Supplementary Information). Other causes: FAP (n = 10), polycystic liver disease (n = 4), ischemic cholangiopathy (n = 2), and cholangiocarcinoma (n = 1). 2 Defined by Olthoff et al (29) .
One-year patient and graft survival rates were 87.5% and 84.5%, respectively. We recorded 30 deaths in the entire cohort, mainly related to infection (bacterial infection, n = 8; fungal infection, n = 6; viral infection, n = 3), HCV recurrence (n = 4), neoplasia (n = 3), stroke (n = 2), and other causes (n = 4). We found no significant differences in the overall unadjusted patient or graft survival after LT according to the donor MBL2 haplotype group (Table 1) . However, in the cumulative hazard analysis for recurrent time-to-event data, 3-month and 1-year bacterial infection-related mortality was significantly higher in LT recipients of MBL-deficient versus MBL-sufficient livers (49.7% vs. 37.5% and 65.8% vs. 56.1%, respectively; p = 0.0097; Figure 2 ). Using the Andersen-Gill model to assess the risk of mortality in LT recipients with episodes of bacterial infection, recipients of an MBL-deficient liver and HCV-positive serology were the only independent predictors of 1-year bacterial infectionrelated mortality (Table 4; see supplementary table for  univariate analysis) .
Fungal infections, viral infections, and biopsy-proven rejection
The percentage of LT recipients who developed fungal or viral infection within 1 year after LT is shown in Table 2 . The incidence and number of fungal and viral infection episodes and the number of biopsy-proven rejection episodes were comparable between LT recipients of MBLdeficient and MBL-sufficient livers (Tables 2 and 3 ). We could not detect any significant differences in the site of infection or microbial isolates in our cohort of LT recipients regarding the donor MBL2 haplotype group (Table 3) .
Interplay between donor and recipient MBL2 genotype on the risk of bacterial infection We did not find any significant difference between the baseline or outcome variables according to the recipient MBL2 genotype. However, we found a slight interplay between donor and recipient MBL genotype regarding the risk of bacterial infection and pneumonia (Table 5) . MBL-deficient donor-MBL-deficient recipient "pairs" had the higher IRR of bacterial infection, while MBL-sufficient donor-MBL-sufficient recipient "pairs" were the least likely to develop bacterial infection and pneumonia. MBLdeficient recipients had a higher risk of pneumonia compared with MBL-sufficient recipients, but this observation was only significant among those receiving a liver from an MBL-deficient donor.
Discussion
Our main findings confirm that donor MBL-deficient livers confer to the LT recipients a higher risk of bacterial infections after LT, regardless of the recipient haplotype. This increased risk of bacterial infection starts early after LT and is particularly high for bacterial pneumonia. The severity of bacterial infection episodes in LT recipients of MBL-deficient livers was higher as shown by an increased incidence of bacterial septic shock and a higher 1-year bacterial infection episoderelated mortality compared with recipients of MBLsufficient livers.
In the current study, we performed a repeated-event analysis of infections and mortality in a large cohort of LT recipients by using the CDC definitions for "infection" and the current definitions of "sepsis" (11, 14) . In this way, we were able to overcome the inconsistent data regarding the role of donor MBL deficiency in the risk of infection and infection-related mortality after LT (16) . The results of a repeated-events analysis may significantly differ from those provided by a first-event analysis (17) and are more robust to ascertain the role of predisposing factors for bacterial infections and their severity (18) . In our cohort, 45% of bacterial infection episodes would have been lost in a per-patient analysis. Moreover, our study includes a large well-defined and representative cohort of contemporary LT recipients. The incidence of BPAR, biliary complications, and 1-year patient and graft survival rates were comparable between the study cohort and the 322 recipients who underwent LT during the same period in our center and were excluded from the study. In per-patient analysis, recipients of an MBL-deficient liver graft were significantly associated with a higher inicidence of bacterial infection and septic shock. Other bacterial infections sites include skin and mucosa (n = 14), central nervous system (n = 1), and nonidentified site (n = 7).
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Other fungal infections sites include histoplasmosis (n = 1), intra-abdominal (n = 2), central venous catheter (n = 2), central nervous system (n = 1), and urinary (n = 1). 3 Biopsy-proved CMV disease includes pneumonitis (n = 3), colitis (n = 5), and esophagitis (n = 1). 4 Other Gram negative bacteria: Proteus (n = 4), Citrobacter (n = 1), Bacteroides (n = 2), Neisseria flavescens (n = 1), Moraxella catarrhalis (n = 1), and H. influenzae (n = 1).
This observation reinforces the representativeness of our study cohort to assess the risk of infection and death after LT.
Infections after LT are common and are a significant cause of morbidity and mortality. MBL serum levels achieve a steady state within the first 48 hours after LT according to the MBL haplotype of the donor (5). The increased risk of bacterial infections in LT recipients of MBL-deficient livers was already detectable within 48 h after LT, and the risk of bacterial infection remained markedly increased within 90 days after LT, supporting the crucial role that innate immunity plays during the period of greatest drug-induced immunosuppression. LT recipients of MBL-deficient livers also more frequently had recurrent infections, in agreement with a recent study in an adult population (4) . As expected, the MELD score was also a risk factor for bacterial infection after LT (19) . An interesting observation of our study was the increased risk of developing pneumonia in LT recipients of MBL-deficient livers throughout the follow-up period. The reason for this finding is not completely understood but is in agreement with previous studies in newborns and immunosuppressed patients (i.e. patients with rheumatoid arthritis, erythematosus lupus) (20) . The IRR of bacterial infection and bacterial pneumonia seems to be driven mainly by the donor 0 s MBL2 genotype and is only partially influenced by the recipient MBL2 genotype, supporting the role of extrahepatic production of MBL as a modulator of the risk of bacterial infection and pneumonia. MBL becomes detectable in bronchoalveolar lavage fluid of patients with respiratory infections (21) , suggesting its importance as a local defense mechanism against microbial invasion in the respiratory epithelium and mucus layer.
Remarkably, this study confirms that LT recipients of an MBL-deficient liver have a greater risk of developing bacterial septic shock and bacterial infection-related mortality after LT. This infection-related adverse outcome in LT recipients of MBL-deficient livers could be explained by a lower ability to recognize pathogen-associated molecular patterns, leading to an increased microbial burden and/or to an increased proinflammatory response. MBL downregulates tumor necrosis factor a and interleukin-6, two key molecules in the proinflammatory cytokine cascade released by monocytes, macrophages, and lymphocytes in response to infection (1) . Patients with low levels of serum MBL display an increased risk for systemic inflammatory response syndrome and progression from infection to sepsis and septic shock and a higher mortality (22, 23) . Finally, HCV infection was also a predictor for bacterial infection-related mortality in our series, probably due to the increased risk of bacterial infection in recipients with severe HCV recurrence after LT. Indeed, HCV infection was no longer a predictive factor for bacterial infection or bacterial infection-related mortality when we evaluated only the first 3 months after LT.
The main limitation of this study is its retrospective design. However, we used a consistent definition for infection, the management of recipients was uniform, and we performed a repeated-event analysis. Moreover, the percentage of LT recipients of MBL-deficient livers and the overall incidence of infection, rejection, and survival were comparable to the average results of other series. We could not confirm an increased risk for fungal and CMV infections in recipients of MBL-deficient livers, probably due to the low incidence of these infections in our contemporary cohort. The implementation of preventive strategies in high-risk LT recipients and close monitoring of CMV replication and Aspergillus infection/ colonization in our population probably account for this discrepancy. Therefore, our results do not support a specific CMV prophylaxis depending on the donor or the recipient MBL2 genotype using our protocol (preemptive strategy in CMV-positive recipients and 3-month prophylaxis with valganciclovir in high-risk recipients defined as donor CMV-positive with recipient CMV-negative). In our study, we observed an increased risk for P. aeruginosa infection in LT recipients of MBL-deficient donors. Some authors have shown that MBL binds to P. aeruginosa in a mannose-specific and calcium-dependent manner (24) (25) (26) . In fact, studies in humans and mice suggest that MBL deficiency predisposes the host to infection and systemic spread of infection by P. aeruginosa (24) (25) (26) . Because the etiology of bacterial infection after LT is strongly driven by antibiotic exposure before LT, we believe that the increased incidence of P. aeruginosa infection was probably related to bacterial selection due to our pretransplantation antibiotic policy in patients with advanced cirrhosis.
Our results suggest that MBL2 genotyping of liver donors could provide information about the risk of bacterial infection, pneumonia, septic shock, and bacterial infection-related mortality after LT. Donor and recipient genotyping is feasible in 4-6 hours by using commercial kits and automated analyzers with comparable costs to donor HLA typing. We do not believe that antibiotic prophylaxis regimen should be changed in all LT recipients of MBL-deficient donor livers. However, LT recipients with a MELD score >22 at transplantation receiving an MBL-deficient donor liver have the highest risk of bacterial infection, which is further increased if the recipient is also MBL deficient. Our data support assessing bacterial colonization or prolonging antibiotic prophylaxis in these highly selected patients. Our results also suggest the potential use of MBL supplementation during a limited time after LT in recipients of a MBL-deficient donor liver. Although this approach seems to be safe and has already been proposed in MBL-deficient children with cancer (27) , its feasibility is hampered because recombinant MBL is not currently commercially available. Whether other strategies, such as omega-3 fatty acids infusion (28) , can increase MBL serum levels in humans warrants further investigation.
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